Article: | MedLuna.com

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2017 Oct 4

PMID 28971213

Citations 1

Authors

C Kneitz

J Atta

H Burkhardt

Affiliations

Soon will be listed here.

Abstract

Hematological alterations can often be observed during rheumatic diseases. The effects can be clinically severe, ranging from anemia of different grades of severity, through increased risk of hemorrhage due to thrombocytopenia up to severe infections as a result of high-grade leukocytopenia. The clinical sequelae for patients are predominantly determined by the extent of cytopenia. The underlying disease itself can initially be considered as the cause. Examples are anemia as a result of chronic inflammation, antibody-mediated thrombocytopenia as in systemic lupus erythematosus (SLE) or granulocytopenia within the framework of Felty's syndrome. Immunosuppressive treatment also often leads to alterations in the blood constituents. Although some substances, such as cyclophosphamide can suppress all three cell types, there are also selective effects, such as isolated thrombocytopenia under treatment with tocilizumab and JAK inhibitors. The differential diagnostic clarification of cytopenia can be difficult and necessitates a systematic work-up of the course of the disease and the subsequent treatment. The reviews of anemia, leukocytopenia and thrombocytopenia presented here summarize the most important components of the differentiation of hematological alterations in patients with rheumatic diseases.

Citing Articles

[Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].

Stefanski A, Dorner T, Kneitz C Z Rheumatol. 2023; 83(2):87-97.

PMID: 37644129 DOI: 10.1007/s00393-023-01408-4.

References

Hansen O, Hansen T, Jans H, Hippe E . Red blood cell membrane-bound IgG: demonstration of antibodies in patients with autoimmune haemolytic anaemia and immune complexes in patients with rheumatic diseases. Clin Lab Haematol. 1984; 6(4):341-9. DOI: 10.1111/j.1365-2257.1984.tb00561.x. View

Bashal F . Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J. 2013; 7:87-95. PMC: 3816272. DOI: 10.2174/1874312901307010087. View

Salmon J, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O . Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015; 1(1):e000034. PMC: 4612695. DOI: 10.1136/rmdopen-2014-000034. View

Besada E, Koldingsnes W, Nossent J . Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM. 2012; 105(6):545-50. DOI: 10.1093/qjmed/hcs015. View

Fayyaz A, Igoe A, Kurien B, Danda D, James J, Stafford H . Haematological manifestations of lupus. Lupus Sci Med. 2015; 2(1):e000078. PMC: 4378375. DOI: 10.1136/lupus-2014-000078. View

Kado R, Sanders G, McCune W . Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Curr Opin Rheumatol. 2017; 29(3):228-233. DOI: 10.1097/BOR.0000000000000377. View

Starkebaum G, Arend W . Neutrophil-binding immunoglobulin G in systemic lupus erythematosus. J Clin Invest. 1979; 64(4):902-12. PMC: 372198. DOI: 10.1172/JCI109556. View

Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K . Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2016; 56(1):46-57. DOI: 10.1093/rheumatology/kew329. View

Wahle M . [Anemia in patients with rheumatoid arthritis]. Z Rheumatol. 2012; 71(10):864-8. DOI: 10.1007/s00393-011-0925-0. View

10.

Papadaki H, Kritikos H, Valatas V, Boumpas D, Eliopoulos G . Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood. 2002; 100(2):474-82. DOI: 10.1182/blood-2002-01-0136. View

11.

Capsoni F, Sarzi-Puttini P, Zanella A . Primary and secondary autoimmune neutropenia. Arthritis Res Ther. 2005; 7(5):208-14. PMC: 1257445. DOI: 10.1186/ar1803. View

12.

Starkebaum G . Leukemia of large granular lymphocytes and rheumatoid arthritis. Am J Med. 2000; 108(9):744-5. DOI: 10.1016/s0002-9343(00)00386-7. View

13.

Newman K, Akhtari M . Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus. Autoimmun Rev. 2011; 10(7):432-7. DOI: 10.1016/j.autrev.2011.01.006. View

14.

Abdulkader R, Dharmapalaiah C, Rose G, Shand L, Clunie G, Watts R . Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol. 2014; 41(5):858-61. DOI: 10.3899/jrheum.130526. View

15.

Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen B . IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9):1271-6. PMC: 398432. DOI: 10.1172/JCI20945. View

16.

Dessypris E, Baer M, Sergent J, Krantz S . Rheumatoid arthritis and pure red cell aplasia. Ann Intern Med. 1984; 100(2):202-6. DOI: 10.7326/0003-4819-100-2-202. View

17.

Carli L, Tani C, Vagnani S, Signorini V, Mosca M . Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact--A systematic literature review. Semin Arthritis Rheum. 2015; 45(2):190-4. DOI: 10.1016/j.semarthrit.2015.05.009. View

18.

van Vollenhoven R, Fleischmann R, Furst D, Lacey S, Lehane P . Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015; 42(10):1761-6. DOI: 10.3899/jrheum.150051. View

19.

Danza A, Ruiz-Irastorza G . Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013; 22(12):1286-94. DOI: 10.1177/0961203313493032. View

20.

Aster R . Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest. 1966; 45(5):645-57. PMC: 292742. DOI: 10.1172/JCI105380. View